Latest Advances in the Management of Advanced NSCLC with ALK or ROS1 Mutations

EP: 1.Expert Insights on Recent Advancements in LS-SCLC

EP: 2.Key Updates in the Treatment of ES-SCLC

EP: 3.Expert Perspectives on Tarlatamab in ES-SCLC

EP: 4.Looking Ahead in SCLC: ADCs and Other Novel Agents

EP: 5.Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC

EP: 6.Personalizing Adjuvant Targeted Therapy in Early-Stage NSCLC

EP: 7.New Targeted Approaches in Unresectable Early-Stage NSCL

EP: 8.Navigating New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC

EP: 9.Expert Insights for Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond

Now Viewing

EP: 10.Latest Advances in the Management of Advanced NSCLC with ALK or ROS1 Mutations

EP: 11.Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations

EP: 12.Tailoring Immunotherapy Strategies for Advanced NSCLC

Video content above is prompted by the following:

• Briefly comment on the 5-year follow-up data from the CROWN trial and discuss how these findings inform your first-line treatment approach and in managing ALK-positive NSCLC with brain metastasis. (Solomon BJ, et al. J Clin Oncol. 2024;42(29):3400-3409.)
• Do you prefer starting patients at the full dose with subsequent dose reductions if necessary, or initiating at a lower dose and titrating upward as tolerated?
• For patients receiving lorlatinib in the frontline setting, how do you manage treatment following disease progression?
• Briefly discuss your approach to biomarker testing for ROS1 alterations and how recent data inform your treatment decisions in this space.
• How do the latest data from TRIDENT-1 trial inform your treatment approach for patients with ROS1 alterations and CNS involvement? (Drilon A, et al. NEJM. 2024;390:118-131.)
• Briefly comment on the TRUST-I/II (Perol, M et al. ESMO 2024. Abs 1289P) and ARROS-1 (Besse B, et al. ESMO 2024. Abs 1256MO) trials. Where do you see these novel agents (eg, taletrectinib and zidesamtinib) fitting in the treatment paradigm?